Predictive Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
AGPU$7.64+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 · 2022 | |||
| Cash flows from operating activities: | |||
| Net loss | $(13,983,967) | $(25,737,634) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 739,316 | 1,313,075 | |
| Vesting expense | 2,038 | 166,312 | |
| Common stock issued to non-employees | 299,430 | 356,125 | |
| Gain on valuation of equity-linked instruments and derivative liability | (12,457) | (115,647) | |
| Loss on impairment of goodwill | - | 7,231,093 | |
| Loss on impairment of finite-lived intangible assets | - | 3,349,375 | |
| Loss on impairment of property and equipment | 162,905 | 185,469 | |
| Loss on property and equipment disposal | 903 | 14,346 | |
| Changes in assets and liabilities: | |||
| Accounts receivable | (2,501) | 23,000 | |
| Inventories | (63,881) | (42,808) | |
| Prepaid expense and other assets | (43,377) | 78,425 | |
| Accounts payable | 398,575 | (78,322) | |
| Accrued expenses and other liabilities | (397,851) | 869,987 | |
| Contract liabilities | (293,982) | 41,819 | |
| Other long-term liabilities | 5,459 | (25,415) | |
| Net cash used in operating activities: | (13,189,390) | (12,370,800) | |
| Cash flows from investing activities: | |||
| Purchase of property and equipment | (276,352) | (419,869) | |
| Acquisition of intangibles | (26,019) | (55,828) | |
| Net cash used in investing activities: | (302,371) | (475,697) | |
| Cash flows from financing activities: | |||
| Proceeds from issuance of common stock and warrants, net | - | 6,507,050 | |
| Proceeds from issuance of common stock pursuant to equity line | - | 236,009 | |
| Repurchase of common stock upon vesting of restricted stock units | (1,510) | (27,654) | |
| Proceeds from note payable | 364,721 | - | |
| Repayment of note payable | (214,313) | - | |
| Net cash provided by financing activities | 148,898 | 6,715,405 | |
| Net decrease in cash | (13,342,863) | (6,131,092) | |
| Cash at beginning of period | 22,071,523 | 28,202,615 | |
| Cash at end of period | $8,728,660 | $22,071,523 | |
| Supplemental disclosure for cash flow information: | |||
| Cash payments for interest | $13,904 | $3,821 | |
| Non-cash transactions: | |||
| Adjustment to goodwill for acquisition of zPREDICTA contract liabilities | $ | - | $373,303 |
| Right-of-use assets obtained in exchange for lease liabilities | 2,997,181 | - | |
| Series F Preferred Stock dividend | 794 | - | |
| Common stock issued to settle accrued board of directors’ and advisory board compensation | 189,896 | - | |
| Redemption of Series F Preferred Stock | (794) | - | |
| Common stock issued in connection with reverse stock split | 253 | - | |
| Common stock issued to management upon vesting of restricted stock units | 4,934 | - | |
See accompanying notes to unaudited consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.